Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply

Viking Therapeutics, Inc.

Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.
CordenPharma commits to multi-ton annual API supply; dedicated lines for 100M autoinjectors and 100M vial/syringe units.
Annual oral tablet capacity exceeds 1 billion units; capacities are expandable at Viking's option.
Phase 3 subcutaneous VK2735 trial planned to start Q2 2025; oral Phase 2 VENTURE trial ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.